0 reviews
Advanced molecular AI platform integrating deep learning and physics-based ML
Proprietary GEMS platform for AI-driven molecular design
Pearl foundation model for protein–ligand structure prediction
Reported performance exceeding AlphaFold 3 on key protein–ligand benchmarks
Focus on unlocking tough, chemically complex protein targets
Industry-leading speed with high potency and selectivity in discovery workflows
Scalable small-molecule discovery across large chemical spaces
Active internal pipeline across multiple therapeutic areas (e.g., immunology, inflammation)
Dedicated AI research advancing state-of-the-art molecular modeling
Drug pipeline development enabled by AI-guided design and triage
Protein–ligand binding pose prediction to guide medicinal chemistry
Strategic AI-focused collaborations (e.g., with Incyte)
Founded in 2019 with strong investor backing (a16z, Fidelity, BlackRock, NVIDIA)
Experienced leadership with deep pharma and AI expertise
Biotech focus on AI-enabled small-molecule therapeutics
If you've used this product, share your thoughts with other customers
Join a mission-driven AI community at DeepMind
Revolutionize AI Characters with CharacterGPT V2
Effortlessly Integrate Your Data with GPT Using Godly.AI
Convert Your AI Ideas Into Money Making Products with The GPT Factory
Empower Creativity with GenAI's Multimodal Content Generation.
Revolutionize Learning with Doctrina AI's Tailored Education Tools
Rapidly optimize potency and selectivity using AI-guided design and structure–activity insights from GEMS.
Predict protein–ligand structures at scale with Pearl to prioritize designs and de-risk experiments.
Unlock hard protein targets previously considered intractable to expand the addressable target space.
Accelerate hit finding and lead optimization to compress cycle times and improve portfolio velocity.
Leverage platform expertise via partnerships to build high-quality pipelines with fewer resources.
Generate high-confidence binding poses to inform assay design and crystallography or cryo-EM efforts.
Triage large design spaces efficiently, focusing wet-lab effort on the most promising candidates.
Structure AI-driven collaborations (e.g., with Incyte) to pursue new small-molecule programs jointly.
Apply molecular AI to immunology and inflammation targets to advance differentiated candidates.
Evaluate platform differentiation, benchmark leadership, and pipeline scalability in molecular AI.